Literature DB >> 2111860

Effect of chronic renal failure on high-density lipoprotein kinetics.

M M Fuh1, C M Lee, C Y Jeng, D C Shen, S M Shieh, G M Reaven, Y D Chen.   

Abstract

Plasma lipid and lipoprotein concentration and high density lipoprotein (HDL) kinetics were determined in control subjects and patients with chronic renal failure (CRF). Results demonstrated that plasma triglyceride (TG) concentration was significantly higher (P less than 0.001) in patients with CRF, associated with a significant increase in plasma VLDL-cholesterol (P less than 0.002) and a significant decrease (P less than 0.05) in plasma HDL-cholesterol concentration. The rate of removal of 125I-apoAI/HDL from plasma was slower (P less than 0.001) in the patients with CRF, resulting in an increase in the residence time of 125I-apoAI/HDL (P less than 0.001) and a decrease in the fractional catabolic rate (P less than 0.001). Since plasma apoAI concentration was lower in patients with CRF, total apoAI/HDL synthetic rate was also significantly (P less than 0.05) decreased. These data provide support for the view that low plasma HDL-cholesterol concentrations in patients with CRF are related to decreases in the synthetic rate of apoAI/HDL.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2111860     DOI: 10.1038/ki.1990.114

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  5 in total

1.  Lower HDL-C and apolipoprotein A-I are related to higher glomerular filtration rate in subjects without kidney disease.

Authors:  Jan A Krikken; Ron T Gansevoort; Robin P F Dullaart
Journal:  J Lipid Res       Date:  2010-03-08       Impact factor: 5.922

2.  Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo.

Authors:  Gunther Marsche; Sasa Frank; Andelko Hrzenjak; Michael Holzer; Sabine Dirnberger; Christian Wadsack; Hubert Scharnagl; Tatjana Stojakovic; Akos Heinemann; Karl Oettl
Journal:  Circ Res       Date:  2009-01-29       Impact factor: 17.367

3.  Pharmacokinetic and pharmacodynamic profile of rosuvastatin in patients with end-stage renal disease on chronic haemodialysis.

Authors:  Bruce K Birmingham; Suzanne K Swan; Tom Puchalski; Pat Mitchell; Connie Azumaya; Julie Zalikowski; Yi Wang
Journal:  Clin Drug Investig       Date:  2013-04       Impact factor: 2.859

Review 4.  Role of HDL dysfunction in end-stage renal disease: a double-edged sword.

Authors:  Hamid Moradi; Nosratola D Vaziri; Moti L Kashyap; Hamid M Said; Kamyar Kalantar-Zadeh
Journal:  J Ren Nutr       Date:  2013-05       Impact factor: 3.655

5.  Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production.

Authors:  Hamid Moradi; Hamid M Said; Nosratola D Vaziri
Journal:  Transl Res       Date:  2012-12-03       Impact factor: 7.012

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.